Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD.

[1]  F. Martinez,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[2]  J. Vestbo,et al.  Cardiovascular Morbidity in COPD: A Study of the General Population , 2011, COPD.

[3]  R. Dahl,et al.  Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison , 2010, European Respiratory Journal.

[4]  C. Jenkins,et al.  Cardiovascular events in patients with COPD: TORCH Study results , 2010, Thorax.

[5]  J. Lötvall,et al.  Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. , 2010, American journal of respiratory and critical care medicine.

[6]  H. Magnussen,et al.  Efficacy of a new once-daily long-acting inhaled β2-agonist indacaterol versus twice-daily formoterol in COPD , 2010, Thorax.

[7]  Ulrich Bothner,et al.  Chronic obstructive pulmonary disease and the risk of cardiovascular diseases , 2010, European Journal of Epidemiology.

[8]  R. Wood‐Baker,et al.  Cardiovascular mortality and morbidity in chronic obstructive pulmonary disease: the impact of bronchodilator treatment , 2010, Internal medicine journal.

[9]  S. Pocock,et al.  Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. , 2009, Pulmonary pharmacology & therapeutics.

[10]  M. Decramer,et al.  Cardiovascular safety of tiotropium in patients with COPD. , 2010, Chest.

[11]  M. Decramer,et al.  Patients With COPD Cardiovascular Safety of Tiotropium in , 2010 .

[12]  M. Decramer,et al.  Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. , 2009, American journal of respiratory and critical care medicine.

[13]  J. Castro‐Rodriguez,et al.  Tiotropium and risk for fatal and nonfatal cardiovascular events in patients with chronic obstructive pulmonary disease: systematic review with meta-analysis. , 2009, Respiratory medicine.

[14]  Joseph Finkelstein,et al.  Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity , 2009, International journal of chronic obstructive pulmonary disease.

[15]  S. Khindri,et al.  A Thorough QT Study on the Effect of Indacaterol on Cardiac Safety in Healthy Subjects. , 2009, ATS 2009.

[16]  P. Zimetbaum,et al.  Arrhythmias in Patients With Chronic Obstructive Pulmonary Disease (COPD): Occurrence Frequency and the Effect of Treatment With the Inhaled Long-Acting Beta2-Agonists Arformoterol and Salmeterol , 2008, Medicine.

[17]  C. Furberg,et al.  Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. , 2008, JAMA.

[18]  A. Pickard,et al.  Risk for Death Associated with Medications for Recently Diagnosed Chronic Obstructive Pulmonary Disease , 2008, Annals of Internal Medicine.

[19]  Liam Ck.  A 4-year trial of tiotropium in chronic obstructive pulmonary disease. , 2008 .

[20]  N. Hanania,et al.  Arformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease: A one year evaluation of safety and tolerance , 2008, Therapeutic advances in respiratory disease.

[21]  E. Kerwin,et al.  Cardiac safety profile of nebulized formoterol in adults with COPD: a 12-week, multicenter, randomized, double- blind, double-dummy, placebo- and active-controlled trial. , 2007, Clinical therapeutics.

[22]  G. Criner,et al.  Cardiac safety of formoterol 12 microg twice daily in patients with chronic obstructive pulmonary disease. , 2007, Pulmonary pharmacology & therapeutics.

[23]  J. Morganroth.  Cardiac Repolarization and the Safety of New Drugs Defined by Electrocardiography , 2007, Clinical pharmacology and therapeutics.

[24]  Judith K Jones,et al.  Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. , 2006, Annals of epidemiology.

[25]  S. Suissa,et al.  Cardiovascular morbidity and mortality in COPD. , 2005, Chest.

[26]  P. Vardas,et al.  Acute electrophysiologic effects of inhaled salbutamol in humans. , 2005, Chest.

[27]  P. Insulander,et al.  Electrophysiologic Effects of Salbutamol, a β2‐Selective Agonist , 2004 .

[28]  S. Launois,et al.  Cardiovascular morbidity in obstructive sleep apnea. , 1999, Progress in cardiovascular diseases.

[29]  Walker,et al.  Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients , 1994 .

[30]  R E Brashear,et al.  Arrhythmias in patients with chronic obstructive pulmonary disease. , 1984, The Medical clinics of North America.